3-(2-chloro-1,1,2-trifluoro-ethoxy)-benzoic acid | 403-71-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-chloro-1,1,2-trifluoro-ethoxy)-benzoic acid
• 英文别名: 3-(2-Chlor-1,1,2-trifluor-aethoxy)-benzoesaeure；3-<1,1,2-Trifluor-2-chlor-aethoxy>-benzoesaeure；3-<2-Chlor-1,1,2-trifluor-ethoxy>-benzoesaeure；3-(2-Chloro-1,1,2-trifluoroethoxy)benzoic acid
• CAS: 403-71-4
• 化学式: C₉H₆ClF₃O₃
• 分子量: 254.593
• InChiKey: GUAWMPQEUFAOQK-UHFFFAOYSA-N

物化性质

• 沸点：
  318.7±42.0 °C(Predicted)
• 密度：
  1.492±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(2-chloro-1,1,2-trifluoro-ethoxy)-benzoic acid 在 氯化亚砜 作用下， 以92%的产率得到3-(2-chloro-1,1,2-trifluoroethoxy)benzoyl chloride
  参考文献：
  名称：

  Changes in the Activity and Selectivity of Herbicides by Selective Fluorine Substitution, Taking Bentranil and Classic® Analogues as Examples

  摘要：

  将氟原子引入2-苯基-4H-3,1-苯并噁嗪-4-酮（苯噁嗪）中，在某些情况下会对其除草性能产生巨大影响，5-氟-2-苯基-4H-3,1-苯并噁嗪-4-酮（'氟苯噁嗪'）被发现是最活性的化合物。它可以由2-氨基-6-氟苯甲酸制备，或通过直接卤素交换5-氯-2-苯基-4H-3,1-苯并噁嗪-4-酮来制备。后一种反应在试验规模上进行了研究，包括高温（350°C）下无溶剂的氟化钾卤素交换。当作为溶剂使用戊磺醚时，220°C时可能发生的一个副反应——部分分解为二苯醚——可以通过添加少量自由基清除剂来防止。通过侧链氯化适当的甲基磺基苯甲酸前体和卤素交换获得了其他具有伪卤素取代的中间体。'氟苯噁嗪'在水稻、谷物和玉米上表现出良好的广谱活性和选择性。在第二个案例研究中，上述氟代蒽醌酸也被发现适合用于通过其苯胺功能的Meerwein反应合成除草磺酰脲（SU）化合物。2-[(4-氯-6-甲氧基-2-嘧啶基)氨基]羰基]氨基]磺酰]-6-氟苯甲酸甲酯是与玉米兼容的SU的一个例子，而未取代的Classic®类似物则不具有选择性。

  DOI：

  10.2533/000942904777678226
• 作为产物：
  描述：

  3-羟基苯甲酸乙酯 在 氢氧化钾 作用下， 以 乙醇 、 丙酮 为溶剂， 生成 3-(2-chloro-1,1,2-trifluoro-ethoxy)-benzoic acid
  参考文献：
  名称：

  Lichtenberger,J.; Rusch,R.E., Bulletin de la Societe Chimique de France, 1962, p. 254 - 262

  摘要：

  DOI：

文献信息

• Current Recommendations for the Treatment of Genital Herpes
  作者：Daniel T. Leung、Stephen L. Sacks

  DOI：10.2165/00003495-200060060-00007

  日期：2000.12

  The incidence of genital herpes continues to increase in epidemic-like fashion. Aciclovir (acyclovir) has been the original gold standard of therapy. The recent addition of famciclovir and valaciclovir as antiherpes drugs has improved convenience as well as the efficacy of treatment. Although aciclovir remains a widely prescribed and reliable drug, its administration schedule falls short of the ease of usage that the newer nucleoside analogues offer, for both episodic and suppressive therapy. Suppression of symptomatic disease and asymptomatic shedding from the genitalia have both become popular approaches, if not the primary targets of antiviral therapy. Knowing that asymptomatic disease leads to most cases of transmission strongly suggests that suppression with antiviral agents could reduce transmission risk in discordant couples. Unfortunately, the role for antivirals in reducing transmission remains to be proven in clinical trials. Neonatal herpes is now successfully treated using aciclovir. Current randomised clinical trials are examining aciclovir and valaciclovir administration, as well as safety and efficacy for post-acute suppressive therapy. Prevention of recurrences in pregnancy is also a topic under investigation, with a view to reducing the medical need for Cesarean section, or alternatively (and far less likely to be accomplished) to protect the neonate. Although resistance is largely limited to the immunocompromised and a change in resistance patterns is not expected, several drugs are available for the treatment of aciclovir-resistant strains of herpes simplex. Foscarnet is the main alternative with proven efficacy in this setting. Unfortunately, administration of foscarnet requires intravenous therapy, although a single anecdote of topical foscarnet efficacy in this setting has been published. Alternatives include cidofovir gel, which is not commercially available but can be formulated locally from the intravenous preparation. Less effective alternatives include trifluridine and interferon. Future possibilities for treatment of genital herpes include a microparticle-based controlled-release formulation of aciclovir and resiquimod (VML-600; R-848). The search for an effective therapeutic vaccine for genital herpes has not been successful to date, although a live virus glycoprotein H-deficient (DISC) vaccine is currently in clinical trials. Recent data suggest that seronegative women are protected (albeit, not fully) by a glycoprotein D recombinant vaccine with adjuvant. Despite the established safety and convenience of current treatment options, better suppressive options and topical treatment options are much needed. Studies using existing agents as potential tools to avoid Cesarean section, or transmission to neonate or partner are ongoing. Both vaccines and antivirals may eventually play a role in prevention of infection.

  生殖器疱疹的发病率继续以流行病的方式增加。阿昔洛韦（aciclovir）一直是治疗的原始金标准。近期，法莫昔洛韦（famciclovir）和瓦尔阿昔洛韦（valaciclovir）作为抗疱疹药物的加入提升了治疗的便利性和疗效。尽管阿昔洛韦依然是一种广泛处方和可靠的药物，但其给药方案不如新一代核苷类似物在发作性和抑制性治疗方面的使用方便。抑制有症状的疾病和无症状的生殖器病毒排泄已成为流行的治疗方法，甚至成为抗病毒治疗的主要目标。考虑到无症状疾病是大多数传播案例的根源，这强烈表明使用抗病毒药物进行抑制治疗可能会降低不一致伴侣之间的传播风险。不幸的是，目前尚需临床试验证实抗病毒药物在减少传播中的作用。新生儿疱疹目前已成功使用阿昔洛韦进行治疗。当前的随机临床试验正在研究阿昔洛韦和瓦尔阿昔洛韦的给药，及其在急性后抑制治疗中的安全性和疗效。预防妊娠期间复发也是一个正在研究的话题，旨在减少剖宫产的医疗需求，或者（较不可能实现的）保护新生儿。尽管抗药性主要限于免疫系统受损的患者，且抗药性模式不太可能发生变化，但目前有几种药物可用于治疗阿昔洛韦耐药型单纯疱疹。福赛那特（foscarnet）是这一领域主要的替代药物，并已证明其有效性。不幸的是，福赛那特的给药需要通过静脉治疗，尽管已经有关于局部福赛那特在此情况下有效性的单个案例报告。其他替代品包括cidofovir凝胶，虽然市面上没有供应，但可以通过静脉制剂在当地制备。不太有效的替代药物包括三氟尿嘧啶和干扰素。未来生殖器疱疹的治疗可能包括基于微球的阿昔洛韦和瑞克莫德的控释制剂（VML-600；R-848）。迄今为止寻找有效的生殖器疱疹治疗疫苗尚未成功，尽管一种缺乏糖蛋白H的活病毒疫苗（DISC）目前在进行临床试验。最新数据显示，阴性血清女性在一定程度上受到含佐剂的糖蛋白D重组疫苗的保护（尽管并非完全）。尽管现有治疗选项已确立其安全性和便利性，但仍迫切需要更好的抑制选项和局部治疗方案。目前有研究正在使用现有药物作为潜在工具，以避免剖宫产或向新生儿或伴侣传播感染。疫苗和抗病毒药物最终可能在预防感染中发挥作用。
• Hydrangea plant named ‘Hokomazone’
  申请人：Horteve Breeding BV

  公开号：USPP032087P2

  公开（公告）日：2020-08-18

  A new cultivar of Hydrangea macrophylla plant named ‘Hokomazone’ that is characterized by its mophead inflorescence with sterile flower sepals that are pink in color with tints of green, its sterile flower sepals with a firm substance, its upright plant habit, and its suitability for use both as a potted plant and as a cut flower.

  一种新的绣球属Hydrangea macrophylla植物品种，名为“Hokomazone”，其特点为：花序呈拖把状，花瓣为粉红色，带有绿色色调，花瓣质地坚实，植株直立，适合用作盆栽植物和切花。
• 4H-3,1-Benzoxazine derivatives
  申请人：BASF Aktiengesellschaft

  公开号：US04315766A1

  公开（公告）日：1982-02-16

  4H-3,1-Benzoxazine derivatives of the formula ##STR1## where R.sup.1, R.sup.2 and Y have the meanings given in the specification, and their use for controlling unwanted plant growth in numerous crops, such as cereals, Indian corn, soybeans and cotton.

  4H-3,1-苯并噁嗪的衍生物的化学式为 ##STR1## 其中R.sup.1，R.sup.2和Y的含义如规范中所述，并且它们可用于控制多种作物中不需要的植物生长，例如谷物，印第安玉米，大豆和棉花。
• Lichtenberger,J.; Rusch,R.E., Bulletin de la Societe Chimique de France, 1962, p. 325 - 329
  作者：Lichtenberger,J.、Rusch,R.E.

  DOI：——

  日期：——
• Synthesis and insecticidal activity of some 2,5-(fluoroalkoxyphenyl)-1,3,4-oxadiazoles and their N,N'-dibenzoylhydrazine precursors
  作者：John P. Idoux、Kathleen S. Gibbs-Rein、John T. Gupton、Glenn N. Cunningham

  DOI：10.1021/je00053a044

  日期：1988.7